FIMMCYTE
FimmCyte develops a novel immune system-based treatment, which demonstrated positive results through early preclinical studies.
FIMMCYTE
Social Links:
Industry:
Biotechnology Medical
Founded:
2022-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.fimmcyte.com
Total Employee:
1+
Status:
Active
Total Funding:
1.24 M CHF
Similar Organizations
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
Investors List
Venture Kick
Venture Kick investment in Grant - FimmCyte
InnoBooster
InnoBooster investment in Grant - FimmCyte
InnoSuisse
InnoSuisse investment in Grant - FimmCyte
Official Site Inspections
http://www.fimmcyte.com
- Host name: 221.171.147.34.bc.googleusercontent.com
- IP address: 34.147.171.221
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "FimmCyte"
FimmCyte | Deplete, Reprogram, Regenerate
At FimmCyte, we are driven by the goal of leading innovation. Our most advanced endeavor is on developing targeted solutions to address endometriosis, a chronic disease that has been …See details»
About - FimmCyte
Explore how FimmCyte’s innovative therapies unlock untapped market potential in women’s health and chronic disease treatment. Learn more about how we can lead the way toward a …See details»
FimmCyte - Crunchbase Company Profile & Funding
Organization. FimmCyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... FimmCyte closed its last …See details»
FimmCyte - Funding, Financials, Valuation & Investors - Crunchbase
FimmCyte is a biotechnology company that engages in the research and treatment of chronic endometriosis disease. New. Resources. Advanced Search. Start Free Trial . ... How much …See details»
Fimmcyte AG – Swiss Biotech
FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to …See details»
New Portfolio Start-Up: FimmCyte - USZ
Apr 11, 2022 FimmCyte will accelerate the path towards an endometriosis cure with the right understanding and technological edge that can lead towards a successful future. To support the progress of curing women’s health, …See details»
Science | FimmCyte
FimmCyte is a pre-clinical biotech company developing innovative treatments for unmet medical needs. Our primary focus is endometriosis, a chronic condition involving fibrosis, with plans to …See details»
FimmCyte - LinkedIn
FimmCyte is changing that. They’re developing a disease-modifying therapy for endometriosis, targeting the condition’s underlying drivers to deliver long-lasting relief, better fertility ...See details»
Meet the start-ups: FimmCyte - BioInnovation Institute
Sep 20, 2022 Endometriosis affect s more than 1 in 10 women of reproductive age worldwide. F or many of these women, it means a life with excruciating pain, infertility, or other severe symptoms. Today, treatment is insufficient and for …See details»
FimmCyte AG - Venturelab
FimmCyte wins CHF 150,000 to advance their non-hormonal, disease-modifying treatment for endometriosis (venturekick.ch) 31.03.2022. A second cohort joins Tech4Eva accelerator (startupticker.ch) 24.02.2022. New projects to fast-track …See details»
FimmCyte 2025 Company Profile: Valuation, Funding & Investors
FimmCyte General Information Description. Operator of a biotechnology company intended to accelerate the path toward an endometriosis cure. The company is developing treatments to …See details»
FimmCyte: The Venture Leader Biotech developing the first disease ...
Aug 23, 2022 This fall, the Venture Leaders Biotech will represent Swiss innovation in the United States. To select the 10 featured startups, a jury of professional investors and medtech …See details»
FimmCyte | VentureRadar
FimmCyte is a biotechnology firm focused on developing a novel treatment for endometriosis that has the potential to be the first disease modifying treatment for the condition. Their approach …See details»
FimmCyte AG - top100startup.ch
News. 17.09.2024 The most promising Swiss biotech startups and scale-ups of 2024, according to investors (TOP 100); 29.02.2024 FimmCyte secures 1 million CHF investment for Non …See details»
From lab to life-changing: How FimmCyte is on track to transform …
Nov 27, 2024 <p>Thanks to advocates’ endless campaigning and increased clinical attention, endometriosis is finally beginning to receive the attention it deserves. ‘Endo Warriors’ – the …See details»
FimmCyte Joins BII’s Venture House Program to Continue Work on …
Sep 5, 2023 Danish biotech startup FimmCyte is joining BioInnovation Institute’s (BII) Venture House, a program designed to further support former BII Venture Lab companies in their next …See details»
FimmCyte – novel endometriosis treatment | Gebert Rüf Stiftung
Oct 2, 2022 At FimmCyte our vision is to develop the first disease modifying treatment for endometriosis. Every tenth woman has endometriosis, but besides pain management and …See details»
Patients - FimmCyte
FimmCyte’s non-hormonal, disease-modifying treatment for endometriosis focuses on directly targeting disease progression without disrupting hormonal balance. This approach reduces …See details»
FimmCyte secures 1 million CHF investment for Non-Hormonal ...
Feb 29, 2024 FimmCyte, an innovative biotech company dedicated to women's health, has announced its latest achievement in improving endometriosis treatment. Securing a CHF 1 …See details»
FimmCyte - EU-Startups
Articles about FimmCyte: March 15, 2024 10 most innovative Swiss startups to watch in 2024 and beyond! March 1, 2024 Weekly funding round-up! All of the European startup funding rounds …See details»